$8.20
13.00% today
Nasdaq, Apr 04, 09:18 pm CET
ISIN
US26817R1086
Symbol
DYN
Sector
Industry

Dyne Therapeutics Inc Stock price

$9.42
-2.90 23.54% 1M
-24.13 71.92% 6M
-14.14 60.02% YTD
-19.34 67.25% 1Y
-1.07 10.20% 3Y
-14.48 60.59% 5Y
-14.48 60.59% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.49 4.94%
ISIN
US26817R1086
Symbol
DYN
Sector
Industry

Key metrics

Market capitalization $1.07b
Enterprise Value $447.32m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.53
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-343.89m
Free Cash Flow (TTM) Free Cash Flow $-294.75m
Cash position $642.27m
EPS (TTM) EPS $-3.35
P/E forward negative
Short interest 12.76%
Show more

Is Dyne Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Dyne Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Dyne Therapeutics Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Dyne Therapeutics Inc forecast:

Buy
93%
Hold
7%

Financial data from Dyne Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 2.21 2.21
10% 10%
-
-2.21 -2.21
10% 10%
-
- Selling and Administrative Expenses 58 58
119% 119%
-
- Research and Development Expense 281 281
34% 34%
-
-342 -342
43% 43%
-
- Depreciation and Amortization 2.21 2.21
10% 10%
-
EBIT (Operating Income) EBIT -344 -344
42% 42%
-
Net Profit -317 -317
35% 35%
-

In millions USD.

Don't miss a Thing! We will send you all news about Dyne Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dyne Therapeutics Inc Stock News

Neutral
GlobeNewsWire
15 days ago
WALTHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases, today announced it has granted inducement equity awards to its newly appointed Chief Financial Officer, Erick J.
Neutral
GlobeNewsWire
15 days ago
- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -
Neutral
GlobeNewsWire
19 days ago
- Continued favorable safety profile for DYNE-251 - - DELIVER Registrational Expansion Cohort is fully enrolled;  data from this cohort planned for late 2025 - - Potential for Biologics License Application submission for U.S. accelerated approval  in early 2026 - WALTHAM, Mass., March 16, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on advanci...
More Dyne Therapeutics Inc News

Company Profile

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Head office United States
CEO John Cox
Employees 191
Founded 2017
Website www.dyne-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today